CDT Equity Inc. (NASDAQ:CDT) Short Interest Update

CDT Equity Inc. (NASDAQ:CDT) was the target of a large increase in short interest in August. As of August 31st, there was short interest totaling 42,243 shares, an increase of 324.4% from the August 15th total of 9,954 shares. Currently, 5.8% of the company’s stock are short sold. Based on an average trading volume of 141,321 shares, the days-to-cover ratio is currently 0.3 days.

CDT Equity Price Performance

Shares of CDT Equity stock opened at $0.25 on Friday. The company has a 50-day moving average of $2.67 and a 200 day moving average of $36.07. The firm has a market cap of $196,750.00, a price-to-earnings ratio of -0.00 and a beta of 1.48. CDT Equity has a 1 year low of $0.23 and a 1 year high of $2,360.00.

CDT Equity (NASDAQ:CDT) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($8.71) EPS for the quarter.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Wall Street Zen raised CDT Equity from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th. Weiss Ratings restated a “sell (e+)” rating on shares of CDT Equity in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

CDT Equity Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.